• 文献标题:   Multifunctional nanosheets based on hyaluronic acid modified graphene oxide for tumor-targeting chemophotothermal therapy
  • 文献类型:   Article
  • 作  者:   HOU L, FENG QH, WANG YT, ZHANG HJ, JIANG GX, YANG XM, REN JX, ZHU XL, SHI YY, ZHANG ZZ
  • 作者关键词:   graphene oxide, hyaluronic acid, photothermal therapy, chemotherapy, cancer, nanomedicine
  • 出版物名称:   JOURNAL OF NANOPARTICLE RESEARCH
  • ISSN:   1388-0764 EI 1572-896X
  • 通讯作者地址:   Zhengzhou Univ
  • 被引频次:   13
  • DOI:   10.1007/s11051-015-2966-9
  • 出版年:   2015

▎ 摘  要

Graphene oxide (GO) with strong optical absorption in the near-infrared (NIR) region has shown great potential both in photothermal therapy and drug delivery. In this work, hyaluronic acid (HA)-functionalized GO (HA-GO) was successfully synthesized and controlled loading of mitoxantrone (MIT) onto HA-GO via pi-pi stacking interaction was investigated. The results revealed that drug-loaded nanosheets with high loading efficiency of 45 wt% exhibited pH-sensitive responses to tumor environment. Owing to the receptor-mediated endocytosis, cellular uptake analysis of HA-GO showed enhanced internalization. In vivo optical imaging test demonstrated that HA-GO nanosheets could enhance the targeting ability and residence time in tumor site. Moreover, the anti-tumor activity of free MIT, MIT/GO, and MIT/HA-GO in combination with NIR laser was investigated using human MCF-7 cells. In vitro cytotoxicity study revealed that HA-GO could stand as a biocompatible nanocarrier and MIT/HA-GO demonstrated remarkably higher toxicity than free MIT and MIT/GO, with IC50 of 0.79 mu g ml(-1). Tumor cell-killing potency was enhanced when MIT/HA-GO were combined with NIR irradiation, and the IC50 of MIT/HA-GO plus laser irradiation was 0.38 mu g ml(-1). In vivo, MIT/HA-GO plus NIR laser irradiation with the tumor growth inhibition of 93.52 % displayed greater anti-tumor effect compared with free MIT and MIT/GO with or without laser irradiation. Therefore, the MIT/HA-GO nanosheets may potentially be useful for further development of synergistic cancer therapy.